Patient and provider determinants associated with the prescription of adjuvant hormonal therapies following a diagnosis of breast cancer in medicaid-enrolled patients

Journal of the National Medical Association

Volumn 101, Issue 11, 2009, Pages 1112-1118

  McLaughlin, John M ^a,b   Balkrishnan, Rajesh ^a,f   Paskett, Electra D ^a,b   Kimmick, Gretchen G ^c,d   Anderson, Roger T ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d and Public Health Sciences   (United States)

^e PENN STATE COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Access; Breast cancer; Health disparities; Urban population

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FEMALE; HEALTH CARE PERSONNEL; HEALTH DISPARITY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; MONOTHERAPY; PATIENT IDENTIFICATION; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 73349110945     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)31106-8     Document Type: Article

References (21)

1. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123(1):21-27.
2. Possinger K. Fulvestrant - a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer. Expert Opin Pharmacother. 2004;5(12):2549-2558.
3. Perez EA. Appraising adjuvant aromatase inhibitor therapy. Oncologist. 2006;11(10):1058-1069.
4. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131-2139.
5. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98(9):1802-1810.
6. Goss PE, Ingle JN, Martino S, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol. 2007;25(15):2006-2011.
7. Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health. 2007;10(5):367-376.
8. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25(25):3846-3852.
9. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst. 2006;98(18):1285-1291.
10. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23(3):619-629.
11. Anderson RT, Camacho FT, Balkrishnan R, et al. Use of cancer registry data for research on patterns of breast cancer care of individuals with Medicaid insurance. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings. 2005;23(16S, part I of II, June 1 suppl):6021 (abstract).
12. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129(1):125-137.
13. Hosmer DW, Lemeshow S. Applied Logistic Regression: Wiley & Sons, Inc; 2000.
14. Meissner HI, Breen N, Taubman ML, Vernon SW, Graubard BI. Which women aren't getting mammograms and why? (United States). Cancer Causes Control. 2007;18(1):61-70.
15. Coughlin SS, Wilson KM. Breast and cervical cancer screening among migrant and seasonal farmworkers: a review. Cancer Defect Prev. 2002;26(3):203-209.
16. Carver CS, Antoni MH. Finding benefit in breast cancer during the year after diagnosis predicts better adjustment 5 to 8 years after diagnosis. Health Psychol. 2004;23(6):595-598.
17. Bazargan M, Lindstrom RW, Dakak A, Ani C, Wolf KE, Edelstein RA. Impact of desire to work in underserved communities on selection of specialty among fourth-year medical students. J Natl Med Assoc. 2006;98(9):1460-1465.
18. Vanderveen KA, Paterniti DA, Kravitz RL, Bold RJ. Diffusion of surgical techniques in early stage breast cancer: variables related to adoption and implementation of sentinel lymph node biopsy. Ann Surg Oncol. 2007;14(5):1662-1669.
19. Finney Rutten LJ, Iannotti RJ. Health beliefs, salience of breast cancer family history, and involvement with breast cancer issues: adherence to annual mammography screening recommendations. Cancer Detect Prev. 2003;27(5):353-359.
20. Ayanian JZ. Race, class, and the quality of medical care. JAMA. 1994;271(15):1207-1208.
21. Gltick S. Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition. Biomed Pharmacother. 2005;59(suppl 2):S321-S322.